These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes. Lau DC; Teoh H Can J Diabetes; 2015 Dec; 39 Suppl 5():S134-41. PubMed ID: 26654857 [TBL] [Abstract][Full Text] [Related]
24. Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release. Hurt RT; Mundi MS; Ebbert JO Diabetes Metab Syndr Obes; 2018; 11():469-478. PubMed ID: 30233224 [TBL] [Abstract][Full Text] [Related]
25. Obesity management among patients with type 2 diabetes and prediabetes: a focus on lifestyle modifications and evidence of antiobesity medications. Nguyen B; Clements J Expert Rev Endocrinol Metab; 2017 Sep; 12(5):303-313. PubMed ID: 30058889 [TBL] [Abstract][Full Text] [Related]
26. Long-term pharmacotherapy for obesity and overweight. Padwal R; Li SK; Lau DC Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004 [TBL] [Abstract][Full Text] [Related]
27. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management. Manigault KR; Thurston MM Consult Pharm; 2016 Dec; 31(12):685-697. PubMed ID: 28074747 [TBL] [Abstract][Full Text] [Related]
29. Update on Office-Based Strategies for the Management of Obesity. Erlandson M; Ivey LC; Seikel K Am Fam Physician; 2016 Sep; 94(5):361-8. PubMed ID: 27583422 [TBL] [Abstract][Full Text] [Related]
30. Pharmacotherapy for the management of obesity. Patel D Metabolism; 2015 Nov; 64(11):1376-85. PubMed ID: 26342499 [TBL] [Abstract][Full Text] [Related]
31. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss. Kelly EM; Tungol AA; Wesolowicz LA J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010 [TBL] [Abstract][Full Text] [Related]
32. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Krentz AJ; Bailey CJ Drugs; 2005; 65(3):385-411. PubMed ID: 15669880 [TBL] [Abstract][Full Text] [Related]
33. Review of pharmacotherapy options for the management of obesity. Bragg R; Crannage E J Am Assoc Nurse Pract; 2016 Feb; 28(2):107-15. PubMed ID: 26119641 [TBL] [Abstract][Full Text] [Related]
34. The safety and efficacy of lorcaserin in the management of obesity. Hess R; Cross LB Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762 [TBL] [Abstract][Full Text] [Related]
36. Can we win the war on obesity with pharmacotherapy? Gotthardt JD; Bello NT Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1289-1297. PubMed ID: 27590007 [TBL] [Abstract][Full Text] [Related]
37. Antiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term management. Jeon WS; Park CY Endocrinol Metab (Seoul); 2014 Dec; 29(4):410-7. PubMed ID: 25559569 [TBL] [Abstract][Full Text] [Related]
38. Effect of antiobesity medications in patients with type 2 diabetes mellitus. Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442 [TBL] [Abstract][Full Text] [Related]
39. Medication use for the treatment of diabetes in obese individuals. Wilding JPH Diabetologia; 2018 Feb; 61(2):265-272. PubMed ID: 28501906 [TBL] [Abstract][Full Text] [Related]
40. New obesity agents: lorcaserin and phentermine/topiramate. Fleming JW; McClendon KS; Riche DM Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]